



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007 OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/567,630-Conf. #2853	
			Filing Date	May 30, 2006	
			First Named Inventor	Kari Alitalo	
			Art Unit	<del>1005</del> 1634	
			Examiner Name	Kapushoc	
Sheet	1	of	2	Attorney Docket Number	28113/39467A

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A7	US-5,750,652	05-12-1998	Artavanis-Tsakonas et al.	
	A8	US-5,780,300	07-14-1998	Artavanis-Tsakonas et al.	
	A9	US-6,004,924	12-21-1999	Ish-Horowitz et al.	
	A10	US-6,083,904	07-04-2000	Artavanis-Tsakonas	
	A11	US-6,121,045	09-19-2000	McCarthy et al.	
	A12	US-6,262,025	07-17-2001	Ish-Horowitz et al.	
	A13	US-6,291,210	09-18-2001	Sakano et al.	
	A14	US-6,380,362	04-30-2002	Watson et al.	
	A15	US-6,433,138	08-13-2002	Zimrin et al.	
	A16	US-6,436,650	08-20-2002	Artavanis-Tsakonas et al.	
	A17	US-2003/0087907-A1	05-08-2003	Greenspan	
	A18	US-2003/0224516	12-04-2003	Dobie	

FOREIGN PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B7	WO-00/06726	02-10-2000	Amgen, Inc.	
	B8	WO-01/12664	02-22-2001	Chiron Corporation	
	B9	WO-02/24221	03-28-2000	Genentech, Inc.	
	B10	WO-03/027285	04-03-2003	Bionomics Ltd.	
	B11	WO-03/047532	06-12-2003	Baylor College of Medicine	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>3</sup>Applicant's unique citation designation number (optional). <sup>4</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>5</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>7</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	C59	Kinzler et al., "Lessons from Hereditary Colorectal Cancer," <i>Cell</i> , 87, 159-170 (1996).			
	C60	Lohela et al., "Lymphangiogenic Growth Factors, Receptors and Therapies," <i>Thrombosis and Haemostasis</i> , 90(2):167-184 (2003).			
	C61	Maillard et al., "Notch and Cancer: Best to Avoid the Ups and Downs," <i>Cancer Cell</i> , 203-205 (2003).			
	C62	Petrova et al., "Effects of Lymphatic Transcription Factor Prox-1 on Cell Cycle Progression," <i>J. Submicro. Cyt. Path.</i> , 32(3):406 (2000).			
	C63	Wigle et al., "An Essential Role for Prox1 in the Induction of the Lymphatic Endothelial Cell Phenotype," <i>EMBO J.</i> , 21(7):1505-1513 (2002).			
	C64	Xia et al., "siRNA-mediated Gene Silencing in Vitro and in Vivo," <i>Nat. Biotech.</i> , 20(10):1006-1010 (2002).			

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010
--------------------	--------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/567,630-Conf. #2853	
			Filing Date	May 30, 2006	
			First Named Inventor	Kari Alitalo	
			Art Unit	<del>1666</del> 1634	
			Examiner Name	Kapushoc	
Sheet	2	of	2	Attorney Docket Number	28113/39467A

/STK/	C65	International Search Report for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	
/STK/	C66	Written Opinion for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010
-----------------------	--------------------	--------------------	------------